Key facts
- This page summarizes George A. Eldridge's Form 4 filing for Aerovate Therapeutics, Inc. (JBIO).
- 11 reported transactions and 4 derivative rows are listed below.
- Accepted by SEC: 11 Mar 2024, 18:00.
George A. Eldridge - 07 Mar 2024 Form 4 Insider Report for Aerovate Therapeutics, Inc. (JBIO)
- Reporting relationship
- Officer Title: Chief Financial Officer and Treasurer
- Issuer ticker
- JBIO
- Reported as of
- 07 Mar 2024
- Net transaction value
- -$593,709
- SEC form
- 4
- Accepted by SEC
- 11 Mar 2024, 18:00:20 UTC
- Prior SEC filing
- 24 Jan 2024
- Next SEC filing
- 14 Mar 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ George A. Eldridge
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
George A. Eldridge filed Form 4 for Aerovate Therapeutics, Inc. (JBIO) on 11 Mar 2024.
Change
- Previous filing in this sequence was filed on 24 Jan 2024.
- Current net transaction value: -$593,709.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AVTE
transaction
Common Stock
Options Exercise
- Transaction value
- $47,906
- Shares
- +22,386
- Change %
- +1142%
- Price
- $2.14
- Shares after
- 24,346
- Date
- 07 Mar 2024
- Ownership
- Direct
- Footnotes
- F1
AVTE
transaction
Common Stock
Sale
- Transaction value
- $559,688
- Shares
- -22,386
- Change %
- -92%
- Price
- $25.00
- Shares after
- 1,960
- Date
- 07 Mar 2024
- Ownership
- Direct
- Footnotes
- F1, F2
AVTE
transaction
Common Stock
Options Exercise
- Transaction value
- $244
- Shares
- +114
- Change %
- +5.8%
- Price
- $2.14
- Shares after
- 2,074
- Date
- 08 Mar 2024
- Ownership
- Direct
- Footnotes
- F1
AVTE
transaction
Common Stock
Sale
- Transaction value
- $2,850
- Shares
- -114
- Change %
- -5.5%
- Price
- $25.00
- Shares after
- 1,960
- Date
- 08 Mar 2024
- Ownership
- Direct
- Footnotes
- F1
AVTE
transaction
Common Stock
Options Exercise
- Transaction value
- $7,347
- Shares
- +3,433
- Change %
- +175%
- Price
- $2.14
- Shares after
- 5,393
- Date
- 11 Mar 2024
- Ownership
- Direct
- Footnotes
- F1
AVTE
transaction
Common Stock
Sale
- Transaction value
- $86,404
- Shares
- -3,423
- Change %
- -63%
- Price
- $25.24
- Shares after
- 1,970
- Date
- 11 Mar 2024
- Ownership
- Direct
- Footnotes
- F1, F3
AVTE
transaction
Common Stock
Sale
- Transaction value
- $263
- Shares
- -10
- Change %
- -0.51%
- Price
- $26.30
- Shares after
- 1,960
- Date
- 11 Mar 2024
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
AVTE
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -1,400
- Change %
- -4.7%
- Price
- $0.000000
- Shares after
- 28,263
- Date
- 07 Mar 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,400
- Exercise price
- $2.14
- Footnotes
- F1, F4
AVTE
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -20,986
- Change %
- -26%
- Price
- $0.000000
- Shares after
- 58,877
- Date
- 07 Mar 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 20,986
- Exercise price
- $2.14
- Footnotes
- F1, F5
AVTE
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -114
- Change %
- -0.19%
- Price
- $0.000000
- Shares after
- 58,763
- Date
- 08 Mar 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 114
- Exercise price
- $2.14
- Footnotes
- F1, F5
AVTE
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -3,433
- Change %
- -5.8%
- Price
- $0.000000
- Shares after
- 55,330
- Date
- 11 Mar 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 3,433
- Exercise price
- $2.14
- Footnotes
- F1, F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 5 footnotes
Footnote F1
This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023.
Footnote F2
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.289, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Footnote F3
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.88, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Footnote F4
A total of 50,850 shares subject to an employee stock option were granted on April 2, 2021, with 25% of this option vested on March 22, 2022, and the remainder vesting in 36 substantially equal monthly installments thereafter.
Footnote F5
A total of 98,676 shares subject to an employee stock option were granted on April 2, 2021, with 25% of this option vested on June 4, 2022, and the remainder vesting in 36 substantially equal monthly installments thereafter.
SEC remarks
Officer Title: Chief Financial Officer and Treasurer